Wize Pharma

Company Overview

Snapshot

Founded in June 1982 by Gideon Stein, Wize Pharma operates with 1–10 employees. The company raised $5.21 million across 3 funding rounds from 1 investor. In March 2021, Wize Pharma was acquired, leading to its delisting from the stock exchange.

Business overview

Wize Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. The company's core product, LO2A, is a drug designed to lubricate and protect ocular surface tissues, currently marketed in Germany, Switzerland, Hungary, and the Netherlands. Wize Pharma engages local and multinational distributors for LO2A and conducts clinical trials, having completed a Phase 2 trial for LO2A in patients with CCH and a Phase 4 study for DES in Sjögren's syndrome patients. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical market.

Strategic signal

In March 2021, Wize Pharma was acquired and subsequently delisted from the stock exchange, signaling a significant strategic shift for the company. This event indicates a complete change in corporate direction, as the company was also reported to be changing its name to Mawson Infrastructure Group Inc. and pivoting towards Bitcoin mining. This transition highlights a departure from its biopharmaceutical focus and a move into a completely different industry, suggesting a re-evaluation of its core business model and future growth strategy.

Company Intelligence Q&A

What was a significant corporate event for Wize Pharma in March 2021?

In March 2021, Wize Pharma was acquired and subsequently delisted from the stock exchange. The company also announced plans to change its name to Mawson Infrastructure Group Inc.

What was the outcome of Wize Pharma's Phase IV study for LO2A in Sjögren's Syndrome patients?

In November 2020, Wize Pharma announced positive topline results from its Phase IV study of LO2A for the treatment of dry eye syndrome in patients with Sjögren's Syndrome.

Did Wize Pharma engage in any strategic transactions in early 2020?

In February 2020, Wize Pharma completed a strategic transaction with Bonus BioGroup, following agreements executed in January 2020.

What was a key development regarding LO2A's market approval in Hungary?

In March 2019, Resdevco, the licensor of LO2A, was granted market approval for the treatment of Sjögren's Syndrome in Hungary.

What was a significant partnership Wize Pharma entered into in 2019?

In February 2019, Wize Pharma signed a joint venture with Cannabics to research and develop cannabinoid formulations for ophthalmic conditions, and in June 2019, completed a milestone for this joint venture.